.png)
The ASCO 2024 annual meeting took place from 31st May to 4th June. A number of firms presented data, and others used this as an opportunity to provide an update on their oncology strategy. We had Eyes On the planners, the expectations, and Key Takes from the meeting. What caught your eye?
ASCO 2024 Planners and Anticipated Presentations & Posters
Many of our network partners covered the recent ASCO conference. They cover not only the conference itself but also prepped for it by reviewing the abstracts and presentations, providing planners, and sharing their key takes from the event. Below is an example of a planner with events this partner planned to cover.
Based on the released abstracts and titles, the presentations from AZN, NVS, GMAB, BNTX, EXEL, and SRRK were highly anticipated:
Novartis, NVS - An oral presentation of the Phase 3 ASC4FIRST trial for Scemblix in 1L CML was expected, while the main PSMAfore presentation for Pluvicto in pretaxane mCRPC was momentarily not listed, its release as an LB may be forthcoming. Still, two supportive PSMAfore oral presentations were to be included. Lastly, an oral presentation for ARVN-partnered ARV-766 Phase ½ in mCRPC was scheduled.
Scholar Rock, SRRK – An oral presentation of a new update from the Phase 1 DRAGON trial for SRK-181 PD-1 resistant tumors was planned. An earlier presentation at SITC 2023 demonstrated support for continued development.
Genmab, GMAB – Offered as a poster, BNTX-partnered acasunlimab (GEN1046, PD-L1x4-1BB) initial Phase 2 data in NSCLC was scheduled to be presented. As a cohort in a LB poster, results of JNJ-partnered subcutaneous Rybrevant’s PALOMA-2 trial in the 1L EGFR NSCLC (+lazertinib) were also on the agenda.
Astra Zeneca, AZN – First presented at ESMO, the intracranial activity of Dato-DXd from the TROPION-Lung05 was to be shared as a poster. In an independent-sponsor LB oral presentation from the I-SPY2.2 trial, attention was to be drawn to Dato-DXd, as well as other presentations. There were also plans for numerous presentations from Lynparza, Enhertu, Tagrisso and Imfinzi.
BioNTech, BNTX – Further to the acasunlimab presentation mentioned earlier, BNT236 (CTLA-4) preliminary Phase 1 results were to be presented in a poster.
Additional topics of interest included talks regarding DREAMM-7 and Blenrep (GSK) and IMROZ and Saclisa (Sanofi). The MF data from TELLOMAK would inform the ability of Innate Pharma to partner lacutamab and Philogen provided crucial data from PIVOTAL with Daromun in neo-adjuvant resectable melanoma.
Key Takeaways from ASCO 2024:
BMPC – Although it is too early to draw conclusions on efficacy, initial activity data for BLU-222 combined with ribociclib and fulvestrant was well-received.
BCYC – BT-8009 from Corbus’s data on SYS6002 received a positive read-through. This nectin-4 ADC demonstrated a DCR of 86% and an ORR of 43% in cervical cancer, promising potential of BT-8009 beyond metastatic urothelial cancer.
COGT - The abstract data and COGT's efficacy data for bezuclastinib + sunitinib from Part 1 PEAK Ph 3 Study were consistent; all grade AEs increased, primarily <Gr3.
MRUS – MCLA-145 showed similar responses in the monotherapy and combination with pembro arms. Higher ORR and a potentially improved safety profile could be achieved by increasing dosing intervals. Aside from this, Petosemtamab with pembro continued demonstrating strong activity in 1L r/m PD-L1 HNSCC with an overall ORR of 67%, no significant overlapping toxicities, and an acceptable safety profile.
JAZZ – With an OS of 18.1 months and 5.2 months in IHC 3+ and IHC2+, respectively, Zanidatamab had an OS of 15.5 months.
PharmaTell Studio Hints
Many of the National and International Medical Conferences are covered in PharmaTell Studio. As shown above, coverage includes planners, advanced commentary on abstracts, conference coverage, and recaps of key takes. Use the Key Word Search function to easily find related materials by typing in the Conference acronym [ASCO] and the year of interest.
If you are a PharmaTell client and can’t access the PharmaTell-specific links, please contact us at helpdesk@pharmatell.com.
If you are not a client and would like to learn more about PharmaTell and a free trial, please email us at info@pharmatell.com, and we will be happy to assist you.